Key Takeaways
- Domestic formulation steady, exports dip: Domestic business grew ~8% despite a September GST disruption, while export formulations fell ~9% on a single-product inventory issue.
- Margins surprised upward: Standalone EBITDA margin rose ~2.57% to 25.46%, driven by a richer product mix and lower material costs, prompting management to raise its full-year margin guidance by 100 bps.
- API business was the standout: API revenue jumped ~28% on higher-margin bulk procurement from European customers, with full-year growth now guided to ~14%.
- Unichem is a multi-year turnaround story: Q2 normalized to ~11% EBITDA margin after a restructuring-heavy Q1, but management sees a 1.5- to 2-year path for meaningful margin expansion, contingent on dossier approvals and API sourcing shifts.
- What to watch next quarter: Whether the domestic recovery sustains past the festive quarter into a seasonally weak Q3, the pace of Unichem’s dossier registrations, and any update on biosimilar clinical trial starts.
Domestic Formulation: Steady Growth, Mix Shift Underway
- 8% growth with a GST speed bump: The domestic formulation business delivered ~8% growth in Q2, held back by GST rate rationalizations in September that caused trade destocking; a recovery was already visible in October.
- Market share gains continue: Ipca’s MAT market share improved from 2.3% to 2.8% year-on-year, and management expressed confidence that growth will stay above market.
- Chronic mix inches up: The share of chronic therapies in Ipca’s portfolio moved from 34% to ~35%, still below the market’s ~40%, leaving room for further mix-driven margin improvement.
- Pain leads, cardiac recovers, antimalarials drag: The pain segment, Ipca’s largest, grew 10–11%. Cardiac rebounded to ~11% growth after a Q1 restructuring that added two new divisions. Antimalarials continued to decline, while cough and cold recovered with 17% growth.
- Field force expansion is an investment, not yet a payoff: The medical rep count rose to ~7,000 with two new cardiac divisions added this year and a cosmetic dermatology division planned. One pain-focused division, Flexicare, started last year and is still loss-making.
A.K. Jain: "Yes, because the product mix is improving, and that's giving the better margin. So we are giving that guideline."
Export Formulations: One Product Obscures an Otherwise Healthy Quarter
- A single-product drag: Export formulations declined ~9% in Q2 solely because of one product where high channel inventories halted production; excluding that product, European business performed well with better margins.
- U.S. business is small but building: Ipca shipped ~6 products to the U.S. in H1, generating ~INR55 crores in revenue, with another 5–6 products under manufacturing. Management reiterated its philosophy of filing only products built on its own APIs, so the filing pace will stay low relative to peers.
- Branded exports on track: Full-year branded export growth is guided to ~9–10%, and management expressed no doubt that target will be achieved.
A.K. Jain: "But overall, for the year, I have no doubt that, that kind of growth will not be achieved."
API Business: The Quarter’s Growth Engine
- 28% growth with a margin kicker: API revenue surged ~28% in Q2, fueled by better business from Europe and Latin America, including bulk procurement of certain low-volume APIs by European customers at higher margins.
- Full-year guidance raised to ~14%: Management expects the API segment to sustain momentum and deliver ~14% growth for FY26.
- Capacity constrains the pipeline: Ipca can develop only 5–6 APIs at a time, and its U.S. filing strategy is built entirely around its own API capacity. Outsourcing is considered only when the API is a negligible part of product cost or a generic commodity.
Unichem: A Multi-Year Turnaround, Not a Quick Fix
- Q2 normalized after a messy Q1: Unichem’s Q1 was hit by a European facility closure (EUR0.35–0.4 crore annual cost now eliminated), an adverse euro move that created a ~INR10–12 crore exchange provision, and restructuring costs. Q2 delivered ~INR60 crores in EBITDA at an ~11% margin, with U.S. business growing ~12%.
- Market share losses are the new headwind: Unichem lost share in two major products due to lower prices and increased competition, compressing gross margins through both price and lower overhead recovery on reduced volumes. Management called this routine in generics and expects recovery in the next cycle.
- The margin path is slow and approval-gated: Management sees Unichem’s margins staying around Q2 levels in the near term, with larger improvement only after dossier approvals and API sourcing shifts kick in, a process pegged at 1.5 to 2 years.
- R&D spend will not fall: Despite analyst questions about potential synergies, management was explicit that Unichem’s R&D expenditure will stay elevated because it must extend dossiers to Europe, Australia, New Zealand, Canada, and ROW markets.
- Cash position is comfortable: Unichem has surplus cash and will not need an infusion even after paying an EU penalty; the Jogeshwari land sale proceeds were realized in Q3 and will further bolster the balance sheet.
- Cross-selling is still a future story: Only two dossiers are registered so far, and Ipca is just beginning to talk to customers; the dossier registration and approval cycle is expected to take two to three years.
A.K. Jain: "The business also has to mature because business starts, so it will take time. So, let's say, I would say it may -- for that margins to go up, it may be around 1.5 to 2 years."
Margins: Mix-Driven Upside, Guidance Lifted
- Standalone EBITDA margin rose ~2.57% to 25.46%: The improvement came despite only ~7% top-line growth, because material costs fell 3–4% on stable procurement prices and a richer product mix, while fuel costs declined and power costs rose only 1% due to renewable energy savings.
- Consolidated margin improved ~2.58% to 21.68%: The uplift was driven almost entirely by Ipca’s standalone performance; Unichem contributed at an ~11% margin.
- Full-year margin guidance raised by 100 bps: Management had previously guided to a ~25 bps margin decline; after the strong Q2, it now expects consolidated margins to be ~1% better than the ~20% baseline in H2, citing an improving product mix and the absence of Q1’s one-off hits.
- Seasonal mix will test the trend: Q2 is a peak quarter; domestic business typically declines in Q3 and Q4, so the margin trajectory depends on whether the mix improvement can offset seasonal volume headwinds.
Pipeline & Strategic Bets: Early Innings on Multiple Fronts
- Biosimilar tech-transfer deal is a capability play, not near-term revenue: Ipca struck a milestone-and-royalty deal to supply drug substance and drug product technology for an older biosimilar to a regulatory consultant. The partner’s ~25% market share on that product will flow to Ipca, and the collaboration is expected to help qualify Ipca’s plants for U.S. FDA and other markets. Management was clear this is not a new revenue stream for FY26.
- Three of seven biosimilars may enter clinical trials next year: Once trials begin, R&D spend is expected to rise from ~4% of turnover to ~4.5–4.75% in the next financial year.
- GLP-1 preparedness is for the next wave, not this one: Ipca lacked E. coli-based R&D capability and is now building a biotech R&D facility for it. Management said the company will not participate in the current phase of GLP-1 products but will be ready for the next phase, with clone synthesis already underway.
- No 505(b)(2) pipeline: Management confirmed neither Ipca nor Unichem has any pipeline of that nature.
A.K. Jain: "So we will not be there in that kind of race for -- in the current phase of the product. But next phase of product, whenever it comes, we'll be there."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Domestic formulation growth | ~10–11% for the full year | FY26 |
| Generic formulation growth | ~8–9% in H2 FY26 | H2 FY26 |
| API full-year growth | ~14% | FY26 |
| Consolidated EBITDA margin | ~1% better than the ~20% baseline (raised from prior guidance of a ~25 bps decline) | H2 FY26 |
| R&D spend | ~4% of turnover, rising to ~4.5–4.75% once biosimilar clinical trials begin | FY26; next financial year |
| Unichem margin improvement | Meaningful expansion only after dossier approvals and API sourcing shifts | 1.5 to 2 years |
| Unichem API sourcing from Ipca | Qualification applications filed; major APIs to start supplying after regulatory clearance | Next financial year, after 6–9 month clearance process |
| Unichem dossier-driven market expansion | Products taken to Europe, Australia, New Zealand, Canada, ROW after 12–18 month registration process | 2 to 3 years |
| Biosimilar clinical trials | 3 of 7 projects expected to enter trials | Next year |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Domestic formulation revenue growth | ~8% YoY |
| Export formulation revenue | ₹493 cr, declined ~9% YoY from ₹541 cr |
| API business revenue | ₹408 cr, +28% YoY from ₹319 cr |
| Standalone EBITDA margin | ~25.46%, improved ~2.57 ppt YoY from 22.89% |
| Consolidated EBITDA margin | ~21.68%, improved ~2.58 ppt YoY from 19.1% |
| R&D spend | 3.91% of turnover, up from 2.7% in Q2 FY25 |
| Full-year consolidated margin guidance | ~20%, expected to be better by ~1% in H2 FY26 |
| Full-year API business growth guidance | ~14% |
| H2 FY26 generic formulations growth guidance | ~8% to 9% |
| Ipca market share (MAT September 2025) | 2.8%, improved from 2.3% in MAT September 2024 |
| Chronic business share of overall Ipca business | ~35%, up from 34% last quarter |
| Pain segment growth | ~10% YoY |
| Cardiovascular segment growth | ~11% YoY |
| CNS segment growth | ~18% YoY |
| Unichem Q2 EBITDA | ~₹60 cr, ~11% margin |
| Ipca U.S. business H1 FY26 revenue | ~₹55 cr |
| Field force | ~7,000 medical reps |